How Analysts View Allergan after Its 1Q18 Earnings

Allergan (AGN) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues, reporting EPS of $3.74 on revenues of $3.7 billion during 1Q18. Analysts expect Allergan’s top line to fall 3.3% to ~$3.9 billion in 2Q18. Its earnings per share are expected to reach $4.03 in 2Q18. The chart below shows analysts’ recommendations over the last 12 months.

Allergan’s stock price has fallen ~39.5% over the last 12 months, and it’s fallen ~9.8% in 2018 year-to-date. Analysts’ estimates show that the stock has a potential to return ~40.5% over the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $207.35 per share, compared to its price of $151.07 per share on May 2.

On May 4, 26 analysts were tracking Allergan stock. Of these analysts, five recommended a “strong buy,” 12 recommended a “buy,” and seven recommended a “hold.” None of the analysts recommended a “sell” for Allergan. The consensus rating for Allergan stands at ~2.2, which represents a “strong buy” for momentum and long-term investors.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 1.5% of its total investments in Allergan (AGN), 3.8% in Mylan NV (MYL), 7.3% in AbbVie (ABBV), and 8.1% in Abbott Laboratories (ABT).

Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!